Biosimilars reimbursement issues.
2026 · 3rd Quarter (July 1 - Sep 30)
BRISTOL-MYERS SQUIBB COMPANY
Filed by TODD STRATEGY GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- TODD STRATEGY GROUP
- Filing UUID
- f4107a17-88f8-4f17-98b8-2f9465201058
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy.
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Literal federal measure citations: H.R.1492, H.R.4299, H.R.7391, H.R.5509
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.